Traumatic Hyphema - ED Care

Key Points

• Exclude open globe before measuring IOP or performing manipulative examination.
• Rebleeding risk is greatest during the first several days and can produce a larger hyphema and higher IOP than the original injury.
• Use a rigid shield, head elevation, activity restriction, and antiemetic therapy to reduce further bleeding and pressure fluctuation.
• Avoid aspirin and NSAIDs when reasonable because they can impair platelet function.
• Cycloplegics and topical corticosteroids are common ophthalmology-directed treatments for pain and inflammation.
• Monitor IOP closely because blood can obstruct trabecular outflow and cause optic-nerve injury.
• Sickle cell disease or trait lowers tolerance for elevated IOP and often lowers thresholds for admission or surgical washout.
• Arrange later evaluation for angle recession and traumatic glaucoma after the acute blood has cleared.

Algorithm

1. Assess mechanism, visual acuity, pupils, and signs of open globe or other serious ocular trauma.
2. If globe integrity is intact, perform slit-lamp examination and measure IOP.
3. Grade the hyphema and assess for retinal, lens, orbital, or neurologic associated injuries.
4. Place a rigid shield, elevate the head, limit strenuous activity, and provide acetaminophen-based analgesia and antiemetic therapy as needed.
5. Start cycloplegic and topical corticosteroid therapy under ophthalmology guidance.
6. If IOP is elevated, use ophthalmology-directed pressure-lowering drops and determine sickle cell status.
7. Admit or escalate for large hyphema, rebleeding, uncontrolled IOP, sickle cell risk, poor follow-up, or associated serious injury.
8. Arrange close follow-up during the first week and later gonioscopy for angle recession.

Clinical Synopsis & Reasoning

Traumatic hyphema results from disruption of iris or ciliary-body vessels, most often after blunt trauma. Blood may appear as suspended red cells or a layered collection in the anterior chamber. The key threats are rebleeding, acute and delayed intraocular pressure elevation, corneal blood staining, optic-nerve injury, associated angle recession, lens damage, retinal injury, and occult open globe. Rebleeding risk is highest during the first several days as the initial clot retracts and lyses, which is why follow-up during the first week matters even when the initial hyphema is small.

Examine visual acuity, pupils, slit-lamp findings, hyphema height, and associated injuries. Intraocular pressure should be measured only after open globe has been excluded. A dilated fundus examination or ocular imaging may be needed to identify retinal tears, detachment, vitreous hemorrhage, or commotio retinae. CT is used when orbital fracture, intraocular foreign body, or severe associated trauma is suspected. Gonioscopy to assess angle recession is usually deferred until the acute hyphema has resolved because manipulation can provoke rebleeding.

Sickle cell disease and sickle cell trait change management because sickled erythrocytes can obstruct trabecular outflow at lower cell burdens and the optic nerve is more vulnerable to perfusion compromise. Ask about known disease or trait and consider testing when status is unknown and ancestry or clinical context makes it relevant. These patients may require earlier ophthalmologic intervention and lower IOP thresholds. Avoid systemic carbonic anhydrase inhibitors and hyperosmotic agents without specialist input because changes in aqueous pH or systemic osmolality can theoretically promote sickling or create other risk.

Treatment Strategy & Disposition

Place a rigid eye shield, keep the head elevated at least 30 degrees when feasible, limit strenuous activity, and control pain and nausea. Avoid aspirin and nonsteroidal anti-inflammatory drugs when an alternative analgesic is appropriate because platelet inhibition may increase rebleeding risk. Topical cycloplegics reduce ciliary spasm and pain. Topical corticosteroids are commonly used to reduce anterior-segment inflammation and are managed by ophthalmology. Routine systemic antifibrinolytic therapy is not universally used because benefits and adverse effects must be balanced.

Treat elevated IOP according to degree, duration, optic-nerve risk, and sickle status. Topical beta-blockers and alpha agonists are commonly used first. Topical carbonic anhydrase inhibitors may be used in some patients without sickle cell disease, while systemic acetazolamide is generally avoided or used cautiously in sickle cell disease or trait. Prostaglandin analogues are sometimes avoided in the acute inflammatory setting. Refractory pressure elevation, persistent large hyphema, corneal blood staining, active rebleeding, or poor clearance may require anterior-chamber washout.

Disposition is individualized. Reliable patients with a small hyphema, controlled IOP, no sickle cell risk, and no serious associated injury can often be managed as outpatients with ophthalmology follow-up within 24 hours and frequent reassessment during the rebleed window. Admit or arrange very close monitoring for large hyphema, uncontrolled IOP, sickle cell disease or trait with elevated pressure, monocular patients, children at risk for amblyopia, significant associated injury, active rebleeding, or unreliable follow-up.

Epidemiology / Risk Factors

• Sports, falls, assault, projectile injuries, and blunt household trauma are common mechanisms.
• Young patients and athletes are frequently affected, but anticoagulation and age-related fragility can complicate injury in older adults.
• Secondary hemorrhage occurs in a minority of cases but accounts for a disproportionate share of complications.
• Sickle cell disease or trait increases the risk of pressure-related optic injury at lower IOP levels.

Investigations

Admission Considerations

Pharmacology

Prognosis / Complications

• Most small uncomplicated hyphemas resolve with good visual outcome under close follow-up.
• Poor outcome is associated with rebleeding, prolonged high IOP, corneal blood staining, associated retinal or optic injury, and open-globe trauma.
• Angle recession can lead to delayed glaucoma even after the hyphema completely resolves.
• Sickle cell disease or trait can increase the risk of optic-nerve damage from pressure elevation and requires earlier escalation.

Patient Education / Counseling

• Explain the reason for head elevation, shield use, and reduced activity during the first several days.
• Advise against aspirin or NSAIDs unless another clinician determines that the cardiovascular indication outweighs the ocular bleeding risk.
• Warn that the eye can rebleed after initial improvement and that sudden pain or vision loss requires urgent reassessment.
• Emphasize next-day ophthalmology follow-up when outpatient care is chosen.
• Explain the need for later glaucoma surveillance even after the blood disappears.

Notes

The most important nuance is that hyphema management is not determined by the amount of visible blood alone. A small hyphema can cause dangerous IOP elevation, especially in a patient with sickle cell disease or trait. Conversely, a larger hyphema with stable pressure and reliable follow-up may be managed without surgery. Pressure, rebleeding, corneal status, associated injuries, and patient-specific risk drive decisions.

The acute episode also creates a long-term glaucoma risk. Angle recession can damage aqueous outflow and produce glaucoma long after vision and anterior-chamber appearance normalize. Patients should leave the acute-care pathway knowing that future pressure surveillance is part of the injury, not an optional unrelated eye exam.

References

1. American Academy of Ophthalmology: Hyphema — Link
2. AAO: Pearls for Managing Hyphema — Link